GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » USCOM Ltd (ASX:UCM) » Definitions » Debt-to-EBITDA

USCOM (ASX:UCM) Debt-to-EBITDA : -2.37 (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is USCOM Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

USCOM's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$2.27 Mil. USCOM's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.78 Mil. USCOM's annualized EBITDA for the quarter that ended in Dec. 2023 was A$-1.29 Mil. USCOM's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -2.37.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for USCOM's Debt-to-EBITDA or its related term are showing as below:

ASX:UCM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.67   Med: -1.69   Max: -0.53
Current: -1.96

During the past 13 years, the highest Debt-to-EBITDA Ratio of USCOM was -0.53. The lowest was -3.67. And the median was -1.69.

ASX:UCM's Debt-to-EBITDA is ranked worse than
100% of 436 companies
in the Medical Devices & Instruments industry
Industry Median: 1.26 vs ASX:UCM: -1.96

USCOM Debt-to-EBITDA Historical Data

The historical data trend for USCOM's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

USCOM Debt-to-EBITDA Chart

USCOM Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -2.47 -3.67 -0.91 -0.53

USCOM Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.02 -0.85 -0.47 -0.60 -2.37

Competitive Comparison of USCOM's Debt-to-EBITDA

For the Medical Devices subindustry, USCOM's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


USCOM's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, USCOM's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where USCOM's Debt-to-EBITDA falls into.



USCOM Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

USCOM's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.263 + 0.829) / -2.071
=-0.53

USCOM's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.269 + 0.779) / -1.286
=-2.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


USCOM  (ASX:UCM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


USCOM Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of USCOM's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


USCOM (ASX:UCM) Business Description

Traded in Other Exchanges
N/A
Address
Level 8, 66 Clarence Street, Suite 2, Sydney, NSW, AUS, 2000
USCOM Ltd is engaged in the development, design, manufacture, and marketing of premium non-invasive cardiovascular and pulmonary medical devices. The company's geographical segment includes Australia, Asia, America, Europe, and Other regions. It generates maximum revenue from Australia. The company offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, SPIROSONIC, a pulmonary function testing device based on multi-path ultrasound technology and the VENTITEST and VENTITEST-S ultrasonic ventilator calibration devices for optimizing respiratory device performance.

USCOM (ASX:UCM) Headlines

No Headlines